Home » Stocks » ADMP

Adamis Pharmaceuticals Corporation (ADMP)

Stock Price: $1.12 USD 0.01 (0.90%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $1.14 +0.02 (1.79%) Feb 26, 7:59 PM
Market Cap 157.11M
Revenue (ttm) 18.43M
Net Income (ttm) -34.71M
Shares Out 76.04M
EPS (ttm) -0.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $1.12
Previous Close $1.11
Change ($) 0.01
Change (%) 0.90%
Day's Open 1.11
Day's Range 1.05 - 1.17
Day's Volume 5,555,431
52-Week Range 0.27 - 2.34

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) ("Company") today announced that it recently received a notice that one of its patent application...

GlobeNewsWire - 3 weeks ago

SAN DIEGO, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), today announced the closing of its underwritten public offering of 46,621,621 shares of its comm...

GlobeNewsWire - 4 weeks ago

SAN DIEGO, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in vari...

GlobeNewsWire - 4 weeks ago

SAN DIEGO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in vari...

GlobeNewsWire - 1 month ago

SAN DIEGO, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has entered into a non-binding letter of intent with a potential buyer fo...

Seeking Alpha - 1 month ago

Adamis Pharmaceuticals finished 2020 with some Malheur with the company receiving its second CRL for ZIMHI. However, the company is a making a strong comeback thus far in 2021. Adamis plans to...

Benzinga - 1 month ago

Fluidigm (NASDAQ: FLDM) shares are trading higher Friday after the company announced it received the CE-IVD mark for its Advanta Dx SARS-CoV-2 RT-PCR Assay. Fluidigm manufactures life science ...

Other stocks mentioned: FLDM, SEEL, BCRX
InvestorPlace - 1 month ago

Adamis Pharma (ADMP) stock is taking off on Friday after a week of positive news for the company, including a deal with Walgreens. The post ADMP Stock: 4 Things to Know About Adamis Pharma Tod...

GlobeNewsWire - 1 month ago

SAN DIEGO, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its SYMJEPI® (epinephrine) Injection products are now available to members o...

Zacks Investment Research - 1 month ago

Adamis (ADMP) submits an investigational new drug (IND) to the FDA for the investigational use of Tempol for the treatment of COVID-19.

InvestorPlace - 1 month ago

Adamis Pharma (ADMP) stock is taking off on Wednesday following news of its possible treatment for the novel coronavirus. The post ADMP Stock Alert: The Covid-19 Treatment News That Has Adamis...

GlobeNewsWire - 1 month ago

SAN DIEGO, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the submission of an Investigational New Drug (IND) to FDA for the inv...

Zacks Investment Research - 1 month ago

Adamis Pharmaceuticals (ADMP) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

GlobeNewsWire - 3 months ago

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that after the close of business and the U.S. markets on November 13th...

Seeking Alpha - 3 months ago

Adamis Pharmaceuticals Corporation's (ADMP) CEO Dennis Carlo on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Adamis (ADMP) delivered earnings and revenue surprises of -150.00% and -47.23%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 3 months ago

SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the third quarter ended September 30, 2020 and provided a b...

GlobeNewsWire - 3 months ago

SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP) (“Adamis”) announced today that it will host an investor conference call on Monday, November 9, ...

Zacks Investment Research - 3 months ago

Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 5 months ago

SAN DIEGO, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in v...

GlobeNewsWire - 5 months ago

SAN DIEGO, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty biopharmaceutical company focused on developing and commercializing products in v...

GlobeNewsWire - 5 months ago

SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the results of its reconvened 2020 annual meeting of stockholders which was in...

Seeking Alpha - 6 months ago

Adamis Pharmaceuticals Corporation (ADMP) CEO Dr. Dennis Carlo on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Adamis (ADMP) delivered earnings and revenue surprises of -85.71% and -21.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 6 months ago

SAN DIEGO, Calif., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the second quarter ended June 30, 2020 and provid...

GlobeNewsWire - 6 months ago

SAN DIEGO, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that in response to Adamis’ Pre-Investigational New Drug (IND) fil...

Zacks Investment Research - 6 months ago

Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 7 months ago

Investors need to pay close attention to Adamis Pharmaceuticals (ADMP) stock based on the movements in the options market lately.

GlobeNewsWire - 7 months ago

SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that, on July 1, 2020, USWM, LLC (“USWM” or “US WorldMeds”) began promoting A...

Benzinga - 8 months ago

Adamis Pharmaceuticals Corp (NASDAQ: ADMP) shares are trading higher on Monday. The company announced a license to commercialize Tempol, a patented investigational drug for the treatment of co...

GlobeNewsWire - 8 months ago

SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today a license  to commercialize Tempol, a novel patented investigation...

Seeking Alpha - 9 months ago

Adamis recently reported their Q1 earnings with a miss on EPS and revenue. The COVID-19 pandemic has had a significant impact on the company's US Compounding sales.

Seeking Alpha - 9 months ago

Adamis Pharmaceuticals Corporation (ADMP) CEO Dennis Carlo on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 9 months ago

SAN DIEGO, May 18, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the first quarter ended March 31, 2020 and provided a busi...

GlobeNewsWire - 9 months ago

SAN DIEGO, May 11, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced it is reacquiring from Sandoz Inc. the rights to its SYMJEPI ® (epinephrine) I...

Zacks Investment Research - 9 months ago

Adamis (ADMP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

GlobeNewsWire - 10 months ago

SAN DIEGO, April 23, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced publication in the peer reviewed journal Molecules, “The Effects of Int...

GlobeNewsWire - 10 months ago

SAN DIEGO, April 21, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its wholly owned drug outsourcing facility, US Compounding Inc. (USC), ha...

Seeking Alpha - 10 months ago

Adamis Pharmaceuticals: Trying To Find A Course Of Action

GlobeNewsWire - 10 months ago

SAN DIEGO, April 15, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation  (NASDAQ: ADMP) today announced that it has received loan proceeds of $3,191,700 (“PPP Loan”) under the Payc...

GlobeNewsWire - 10 months ago

SAN DIEGO, April 01, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its wholly owned drug outsourcing facility, US Compounding Inc. (USC), ...

GlobeNewsWire - 1 year ago

SAN DIEGO, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis” or the “Company”) today announced it has entered into a securities purchase agreement...

Seeking Alpha - 1 year ago

Adamis Pharmaceuticals: Waiting For The Next Move

GlobeNewsWire - 1 year ago

SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today provided an update on the ZIMHI™ New Drug Application (NDA) resubmission pro...

GlobeNewsWire - 1 year ago

SAN DIEGO, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today provided an update on the ZIMHI™ New Drug Application (NDA) resubmission pro...

GlobeNewsWire - 1 year ago

SAN DIEGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that an article entitled “Comparative Pharmacokinetic Analysis of ...

Seeking Alpha - 1 year ago

Adamis Pharmaceuticals Corp (ADMP) CEO Dennis Carlo on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Adamis: Overdue ZIMHI Decision Puts The Brakes On Stock's Downward Trend

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Adamis Pharmaceuticals (ADMP) stock based on the movements in the options market lately.

GlobeNewsWire - 1 year ago

SAN DIEGO, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that as of the close of business today, Adamis has not received an...

About ADMP

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
CEO
Dennis Carlo
Employees
131
Stock Exchange
NASDAQ
Ticker Symbol
ADMP
Full Company Profile

Financial Performance

In 2019, ADMP's revenue was $22.11 million, an increase of 46.58% compared to the previous year's $15.09 million. Losses were -$29.31 million, -24.87% less than in 2018.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for ADMP stock is "Buy." The 12-month stock price forecast is 1.00, which is a decrease of -10.71% from the latest price.

Price Target
$1.00
(-10.71% downside)
Analyst Consensus: Buy